Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Celeste M Boesjes

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Allergy|September 24, 2025
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future DirectionsMarjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten, et al.
JAMA Dermatology|November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Acta Dermato-Venereologica|February 16, 2023
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay RegistryCeleste M Boesjes, Liana F Van der Gang, Nicolaas P A Zuithoff, et al.
JAMA Dermatology|October 18, 2023
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic DermatitisCeleste M Boesjes, Lian F van der Gang, Daphne S Bakker, et al.
The Journal of Dermatological Treatment|June 21, 2021
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registryJart A F Oosterhaven, Lotte S Spekhorst, Junfen Zhang, et al.
Immunohorizons|January 24, 2025
Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitisSara M Tamminga, M Marlot Van Der Wal, Elise S Saager, et al.
Allergy|July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisLotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|December 24, 2022
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
Acta Dermato-Venereologica|February 7, 2024
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay RegistryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Allergy|September 24, 2025
Biologics to Treat Atopic Dermatitis: Effectiveness, Safety, and Future DirectionsMarjolein S de Bruin-Weller, Celeste M Boesjes, Roselie A Achten, et al.
JAMA Dermatology|November 2, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay RegistryLotte S Spekhorst, Marlies de Graaf, Floris Loeff, et al.
Acta Dermato-Venereologica|February 16, 2023
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay RegistryCeleste M Boesjes, Liana F Van der Gang, Nicolaas P A Zuithoff, et al.
JAMA Dermatology|October 18, 2023
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic DermatitisCeleste M Boesjes, Lian F van der Gang, Daphne S Bakker, et al.
The Journal of Dermatological Treatment|June 21, 2021
Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registryJart A F Oosterhaven, Lotte S Spekhorst, Junfen Zhang, et al.
Immunohorizons|January 24, 2025
Single-cell sequencing of human Langerhans cells identifies altered gene expression profiles in patients with atopic dermatitisSara M Tamminga, M Marlot Van Der Wal, Elise S Saager, et al.
Allergy|July 15, 2022
Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitisLotte S Spekhorst, Daphne Bakker, Julia Drylewicz, et al.
Expert Opinion on Biological Therapy|December 1, 2025
Current treatment landscape of atopic dermatitis focusing on real-world evidence of dupilumab treatmentCeleste M Boesjes, Lian F van der Gang, Roselie E Achten, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|December 24, 2022
Dupilumab in daily practice for the treatment of pediatric atopic dermatitis: 28-week clinical and biomarker results from the BioDay registryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
Acta Dermato-Venereologica|February 7, 2024
Real-world Experience of Abrocitinib Treatment in Patients with Atopic Dermatitis and Hand Eczema: Up to 28-week Results from the BioDay RegistryEsmé Kamphuis, Celeste M Boesjes, Laura Loman, et al.
Pageof 2